JP2021518361A5 - - Google Patents

Info

Publication number
JP2021518361A5
JP2021518361A5 JP2020549641A JP2020549641A JP2021518361A5 JP 2021518361 A5 JP2021518361 A5 JP 2021518361A5 JP 2020549641 A JP2020549641 A JP 2020549641A JP 2020549641 A JP2020549641 A JP 2020549641A JP 2021518361 A5 JP2021518361 A5 JP 2021518361A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
peptide
oligonucleotide conjugate
acceptable salt
chimeric peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020549641A
Other languages
English (en)
Japanese (ja)
Other versions
JP7596148B2 (ja
JP2021518361A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/022475 external-priority patent/WO2019178479A1/en
Publication of JP2021518361A publication Critical patent/JP2021518361A/ja
Publication of JP2021518361A5 publication Critical patent/JP2021518361A5/ja
Priority to JP2024159928A priority Critical patent/JP2024163336A/ja
Application granted granted Critical
Publication of JP7596148B2 publication Critical patent/JP7596148B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020549641A 2018-03-16 2019-03-15 アンチセンス送達用キメラペプチド Active JP7596148B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024159928A JP2024163336A (ja) 2018-03-16 2024-09-17 アンチセンス送達用キメラペプチド

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862644202P 2018-03-16 2018-03-16
US62/644,202 2018-03-16
PCT/US2019/022475 WO2019178479A1 (en) 2018-03-16 2019-03-15 Chimeric peptides for antisense delivery

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024159928A Division JP2024163336A (ja) 2018-03-16 2024-09-17 アンチセンス送達用キメラペプチド

Publications (3)

Publication Number Publication Date
JP2021518361A JP2021518361A (ja) 2021-08-02
JP2021518361A5 true JP2021518361A5 (cg-RX-API-DMAC7.html) 2023-08-28
JP7596148B2 JP7596148B2 (ja) 2024-12-09

Family

ID=67908050

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020549641A Active JP7596148B2 (ja) 2018-03-16 2019-03-15 アンチセンス送達用キメラペプチド
JP2024159928A Pending JP2024163336A (ja) 2018-03-16 2024-09-17 アンチセンス送達用キメラペプチド

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024159928A Pending JP2024163336A (ja) 2018-03-16 2024-09-17 アンチセンス送達用キメラペプチド

Country Status (6)

Country Link
US (2) US12370261B2 (cg-RX-API-DMAC7.html)
EP (1) EP3765030A4 (cg-RX-API-DMAC7.html)
JP (2) JP7596148B2 (cg-RX-API-DMAC7.html)
MA (1) MA52148A (cg-RX-API-DMAC7.html)
TW (1) TW202002990A (cg-RX-API-DMAC7.html)
WO (1) WO2019178479A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019079386A1 (en) * 2017-10-17 2019-04-25 Sarepta Therapeutics, Inc. CELL PENETRATION PEPTIDES FOR ANTISENSE ADMINISTRATION
US20250228954A1 (en) * 2020-01-24 2025-07-17 Sarepta Therapeutics, Inc. Designing Antisense Oligonucleotide Delivery Peptides by Interpretable Machine Learning
CA3211038A1 (en) * 2021-02-12 2022-08-18 Oxford University Innovation Limited Cell-penetrating peptide conjugates and methods of their use
WO2026080471A2 (en) 2024-10-07 2026-04-16 Flagship Pioneering Innovations Vi, Llc Compositions of trem conjugates and uses thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5752601A (en) 2000-05-04 2001-11-12 Avi Biopharma Inc Splice-region antisense composition and method
US8129352B2 (en) 2004-09-16 2012-03-06 Avi Biopharma, Inc. Antisense antiviral compound and method for treating ssRNA viral infection
AU2006267051B2 (en) 2005-07-13 2013-03-07 Sarepta Therapeutics, Inc. Antisense antibacterial method and compound
LT2735568T (lt) 2006-05-10 2017-11-27 Sarepta Therapeutics, Inc. Oligonukleotido analogai, turintys katijonines jungtis tarp subvienetų
US20100016215A1 (en) * 2007-06-29 2010-01-21 Avi Biopharma, Inc. Compound and method for treating myotonic dystrophy
WO2009147368A1 (en) * 2008-06-04 2009-12-10 Medical Research Council Peptides
AU2011367230B2 (en) 2011-05-05 2017-08-10 Sarepta Therapeutics, Inc. Peptide oligonucleotide conjugates
EP2755690B1 (en) 2011-08-04 2020-04-01 Merck Sharp & Dohme B.V. Kisspeptide-pentasaccharide conjugates
US9512073B2 (en) 2011-10-27 2016-12-06 Massachusetts Institute Of Technology Amino acid-, peptide-and polypeptide-lipids, isomers, compositions, and uses thereof
ES2727481T3 (es) 2011-11-30 2019-10-16 Sarepta Therapeutics Inc Inclusión inducida de exón en atrofia muscular espinal
US10111962B2 (en) 2012-09-25 2018-10-30 Genzyme Corporation Peptide-linked morpholino antisense oligonucleotides for treatment of myotonic dystrophy
WO2014124952A1 (en) 2013-02-12 2014-08-21 Syddansk Universitet "clickable" alkyne-lna oligonucleotides
EP3760720A1 (en) 2013-03-14 2021-01-06 Sarepta Therapeutics, Inc. Exon skipping compositions for treating muscular dystrophy
HK1220154A1 (zh) * 2013-03-15 2017-04-28 Sarepta Therapeutics, Inc. 改进的用於治疗肌营养不良的组合物
WO2015038933A1 (en) 2013-09-13 2015-03-19 California Institute Of Technology Phosphorylated akt-specific capture agents, compositions, and methods of using and making
CN113105559A (zh) * 2013-12-12 2021-07-13 生命技术公司 增强转染的膜穿透性肽和组合物以及其使用方法
GB201421379D0 (en) 2014-12-02 2015-01-14 Isis Innovation Ltd And Medical Res Council Molecule
WO2017066789A1 (en) 2015-10-16 2017-04-20 Modernatx, Inc. Mrna cap analogs with modified sugar
WO2019079386A1 (en) * 2017-10-17 2019-04-25 Sarepta Therapeutics, Inc. CELL PENETRATION PEPTIDES FOR ANTISENSE ADMINISTRATION
EP3829597A4 (en) * 2018-07-30 2022-05-18 Sarepta Therapeutics, Inc. TRIMER PEPTIDES FOR ANTISENSE ADMINISTRATION

Similar Documents

Publication Publication Date Title
JP2021532784A5 (cg-RX-API-DMAC7.html)
JP2758988B2 (ja) ペプチド核酸
US7910726B2 (en) Amidite for synthesizing modified nucleic acid and method for synthesizing modified nucleic acid
US6441130B1 (en) Linked peptide nucleic acids
JP2024506099A5 (cg-RX-API-DMAC7.html)
US8859490B2 (en) Peptide nucleic acid monomers and oligomers
Mrksich et al. Recognition in the minor groove of DNA at 5'-(A, T) GCGC (A, T)-3'by a four ring tripeptide dimer. Reversal of the specificity of the natural product distamycin
JP2024511955A5 (cg-RX-API-DMAC7.html)
Jain Cγ-Aminopropylene peptide nucleic acid (amp-PNA): Chiral cationic PNAs with superior PNA: DNA/RNA duplex stability and cellular uptake
De Cola et al. Carboxyalkyl peptoid PNAs: synthesis and hybridization properties
US8288516B2 (en) Functional molecule, functional molecule synthesizing amidite and target substance analysis method
JPWO2009028345A1 (ja) 核酸合成用ダイマーアミダイド及び核酸合成方法
AU2020324396B2 (en) Compositions of trofinetide
CN114901673B (zh) 溶液相肽核酸寡聚体的制备方法
Katritzky et al. Chiral peptide nucleic acid monomers (PNAM) with modified backbones
AU2022291626A1 (en) Improved process for preparing imetelstat
US10174075B2 (en) Use of a tetraphenylborate (TPB) salt for the separation of biomolecules
DE69513313T2 (de) Verfahren zur Herstellung von Nukleinsäurebasenderivaten
Hudson et al. The detrimental effect of orotic acid substitution in the peptide nucleic acid strand on the stability of PNA2: NA triple helices
JP2007511573A (ja) 癌の治療のための置換キノリン
US20210163541A1 (en) Method for Preparing PNA Oligomer
JP2023510019A5 (cg-RX-API-DMAC7.html)
WO2001066528A1 (en) Method for storing quaternary ammonium salt
KR20230109301A (ko) 신규한 pna 단량체 및 이를 포함하는 pna 올리고머
US20050187138A1 (en) Peptide beta-strand mimics based on pyridinones, pyrazinones, pyridazinones, and triazinones